Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of “Buy” by Brokerages

Exact Sciences Co. (NASDAQ:EXASGet Rating) has earned a consensus rating of “Buy” from the fifteen analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $113.00.

A number of analysts have commented on the company. The Goldman Sachs Group reduced their price objective on Exact Sciences from $100.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, April 19th. Craig Hallum reduced their price objective on Exact Sciences from $100.00 to $81.00 in a research report on Wednesday, April 27th. Robert W. Baird reduced their price objective on Exact Sciences from $100.00 to $90.00 in a research report on Wednesday, April 27th. Wells Fargo & Company decreased their price target on Exact Sciences from $95.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 23rd. Finally, SVB Leerink lowered their price target on Exact Sciences from $140.00 to $130.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 23rd.

In other Exact Sciences news, CEO Kevin T. Conroy sold 14,409 shares of the firm’s stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $79.55, for a total value of $1,146,235.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sarah Condella sold 2,816 shares of the stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $76.69, for a total transaction of $215,959.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,636 shares of company stock worth $4,443,252. Insiders own 1.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. Marshall Wace LLP raised its holdings in shares of Exact Sciences by 6,721.4% during the third quarter. Marshall Wace LLP now owns 118,420 shares of the medical research company’s stock worth $11,304,000 after acquiring an additional 116,684 shares during the period. Atria Investments LLC increased its stake in Exact Sciences by 35.3% in the 3rd quarter. Atria Investments LLC now owns 11,449 shares of the medical research company’s stock valued at $1,093,000 after buying an additional 2,990 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Exact Sciences by 12.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 34,362 shares of the medical research company’s stock valued at $2,674,000 after buying an additional 3,772 shares during the last quarter. OMERS ADMINISTRATION Corp increased its stake in Exact Sciences by 65.4% in the 3rd quarter. OMERS ADMINISTRATION Corp now owns 33,676 shares of the medical research company’s stock valued at $3,214,000 after buying an additional 13,312 shares during the last quarter. Finally, Ahrens Investment Partners LLC acquired a new stake in Exact Sciences in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 94.45% of the company’s stock.

Shares of EXAS stock opened at $55.00 on Monday. The stock has a 50 day moving average of $66.08 and a two-hundred day moving average of $76.13. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.67. Exact Sciences has a 12 month low of $53.69 and a 12 month high of $133.99. The company has a market capitalization of $9.68 billion, a P/E ratio of -12.73 and a beta of 1.23.

Exact Sciences (NASDAQ:EXASGet Rating) last announced its quarterly earnings data on Tuesday, April 26th. The medical research company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.08. Exact Sciences had a negative return on equity of 21.82% and a negative net margin of 40.26%. During the same period in the prior year, the company posted ($0.18) earnings per share. Sell-side analysts predict that Exact Sciences will post -4.26 earnings per share for the current fiscal year.

About Exact Sciences (Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Further Reading

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.